Last 20.50 GBp
Change Today -0.25 / -1.20%
Volume 13.0K
ODX On Other Exchanges
As of 11:30 AM 09/18/14 All times are local (Market data is delayed by at least 15 minutes).

omega diagnostics group plc (ODX) Snapshot

20.75 GBp
Previous Close
20.75 GBp
Day High
20.75 GBp
Day Low
20.50 GBp
52 Week High
02/25/14 - 35.13 GBp
52 Week Low
11/21/13 - 13.13 GBp
Market Cap
Average Volume 10 Days
0.0070 GBp
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

omega diagnostics group plc (ODX) Related Businessweek News

No Related Businessweek News Found

omega diagnostics group plc (ODX) Details

Omega Diagnostics Group PLC, through its subsidiaries, engages in the manufacture, development, and distribution of medical diagnostic products. The company operates in three segments: Allergy and Autoimmune, Food Intolerance, and Infectious Disease. The Allergy and Autoimmune segment engages in the research, development, production, and marketing of in vitro allergy and autoimmune tests that are used by doctors to diagnose patients with allergies and autoimmune diseases. This segment’s principal products include Allergozyme, Allergodip, and Genesis Elisa. The Food Intolerance segment engages in the research, development, and production of kits that are used in detection of immune reactions to food. It also provides clinical analysis to the general public, clinics, and health professionals, as well as supplies consumer food detective test. This segment’s principal products include Genarrayt microarray, Food Detective, and Foodprint service. The Infectious Disease segment engages in the research, development, production, and marketing of kits that are used in the diagnosis of infectious diseases, such as syphilis, tuberculosis, dengue fever, chagas disease, and malaria. Its principal products comprise Immutrep Syphilis, Micropath Bacterial tests, and Dengue Elisa. The company offers its diagnostic kits and systems to hospitals, blood banks, clinics, and laboratories through distributors in approximately 100 countries worldwide. Omega Diagnostics Group PLC was founded in 1987 and is headquartered in Alva, the United Kingdom.

Founded in 1987

omega diagnostics group plc (ODX) Top Compensated Officers

Founder, Chief Executive Officer, Managing Di...
Total Annual Compensation: 145.0K GBP
Group Finance Director, Company Secretary and...
Total Annual Compensation: 115.0K GBP
Group Sales & Marketing Director and Executiv...
Total Annual Compensation: 110.0K GBP
Compensation as of Fiscal Year 2013.

omega diagnostics group plc (ODX) Key Developments

Omega Diagnostics Group PLC Announces Consolidated Financial Results for the Year Ended March 31, 2014

Omega Diagnostics Group PLC announced consolidated financial results for the year ended March 31, 2014. For the year, the company reported revenue of £11,593,870 against £11,262,898 a year ago. Operating profit was £527,325 against £306,645 a year ago. Profit before taxation was £543,041 against £276,224 a year ago. Profit for the year was £692,851 or 0.7 pence per diluted share against £582,266 or 0.7 pence per diluted share a year ago. Adjusted profit before taxation was £1,095,911 against £778,562 a year ago. Adjusted EPS on profit for the year was 1.2 pence against 1.3 pence a year ago. Cash flow from operating activities was £1,669,107 against £1,014,953 a year ago. Purchase of property, plant and equipment was £478,968 against £308,876 a year ago. Purchase of intangible assets was £1,880,845 against £1,185,133 a year ago.

Omega Diagnostics Group PLC, Annual General Meeting, Aug 28, 2014

Omega Diagnostics Group PLC, Annual General Meeting, Aug 28, 2014., at 11:00 GMT Standard Time. Location: Omega House, Hillfoots Business Village.

Omega Announces Update on its CD4 Technology Transfer Project

Omega announced the update on its CD4 technology transfer project. As reported last month with the interim results, the company selected a preferred manufacturing protocol to proceed to a three-batch validation. The company announced that it has produced a first reference batch which, when tested on patient samples, has produced results which are within the agreed design specification for the accuracy of the test and which demonstrate a significant reduction in the levels of variability previously reported. This is an important milestone in the technology transfer project and the company will proceed to test the protocol with further independent manufacturing runs. The board has successfully completing the three-batch validation and, given the proximity to Christmas, the company will provide a further update early 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ODX:LN 20.50 GBp -0.25

ODX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ODX.
View Industry Companies

Industry Analysis


Industry Average

Valuation ODX Industry Range
Price/Earnings 30.7x
Price/Sales 2.0x
Price/Book 1.3x
Price/Cash Flow 31.8x
TEV/Sales 1.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OMEGA DIAGNOSTICS GROUP PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at